Quadruple SGLT2i/GLP-1RA/ARNI/MRA Therapy for Heart Failure: Maximum Neurohormonal Blockade
Quadruple combination of SGLT2i, GLP-1 RA, ARNI, and MRA provides comprehensive neurohormonal blockade for heart failure, with each agent targeting distinct pathways for additive cardiorenal benefit.
Quick Facts
What This Study Found
Quadruple SGLT2i + GLP-1 RA + ARNI + MRA: comprehensive neurohormonal blockade targeting 4 distinct pathways for additive cardiorenal benefit in heart failure.
Key Numbers
How They Did This
Review of quadruple combination therapy rationale, mechanisms, and evidence for heart failure.
Why This Research Matters
HF mortality remains high. Quadruple therapy attacking four neurohormonal pathways simultaneously could dramatically improve outcomes.
The Bigger Picture
Heart failure therapy is evolving toward comprehensive pathway blockade — similar to how cancer treatment uses combination chemotherapy.
What This Study Doesn't Tell Us
Quadruple therapy evidence mostly extrapolated from individual drug trials. Safety and cost of 4-drug regimen uncertain.
Questions This Raises
- ?Is quadruple therapy safe for all HF patients?
- ?What is the optimal sequencing of adding each drug?
- ?Does the cost-benefit justify quadruple therapy?
Trust & Context
- Key Stat:
- 4 drugs, 4 pathways Quadruple combination attacks heart failure from four different neurohormonal angles simultaneously — the most comprehensive blockade ever attempted
- Evidence Grade:
- Review extrapolating from individual drug trials. Combination evidence limited.
- Study Age:
- Published in 2025.
- Original Title:
- Quadruple combination therapy with SGLT2i, GLP-1RA, ARNI and MRA in heart failure with preserved ejection fraction patients with type 2 diabetes mellitus: A prospective and observational cohort study.
- Published In:
- Kardiologia polska, 84(1), 28-36 (2026)
- Authors:
- Ke, Jiahan, Qiu, Xiaohan, Wang, Min(4), Zeng, Huasu, Wang, Changqian, Zhang, Junfeng, Chen, Kan, Gu, Jun
- Database ID:
- RPEP-15423
Evidence Hierarchy
Frequently Asked Questions
Why four drugs for heart failure?
Each drug targets a different pathway causing heart failure. Together, they provide the most complete treatment possible — like attacking a problem from four different angles simultaneously.
Is this safe?
Individual drugs are proven safe. The combination needs more study, but early evidence and mechanistic rationale support it for appropriate patients.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15423APA
Ke, Jiahan; Qiu, Xiaohan; Wang, Min; Zeng, Huasu; Wang, Changqian; Zhang, Junfeng; Chen, Kan; Gu, Jun. (2026). Quadruple combination therapy with SGLT2i, GLP-1RA, ARNI and MRA in heart failure with preserved ejection fraction patients with type 2 diabetes mellitus: A prospective and observational cohort study.. Kardiologia polska, 84(1), 28-36. https://doi.org/10.33963/v.phj.109920
MLA
Ke, Jiahan, et al. "Quadruple combination therapy with SGLT2i, GLP-1RA, ARNI and MRA in heart failure with preserved ejection fraction patients with type 2 diabetes mellitus: A prospective and observational cohort study.." Kardiologia polska, 2026. https://doi.org/10.33963/v.phj.109920
RethinkPeptides
RethinkPeptides Research Database. "Quadruple combination therapy with SGLT2i, GLP-1RA, ARNI and..." RPEP-15423. Retrieved from https://rethinkpeptides.com/research/ke-2026-quadruple-combination-therapy-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.